Circulating proteins reveal prior use of menopausal hormonal therapy and increased risk of breast cancer.

Autor: Thomas CE; Science for Life Laboratory, Department of Protein Science School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Tomtebodavägen 23, Solna, Stockholm 171 65, Sweden., Dahl L; Science for Life Laboratory, Department of Protein Science School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Tomtebodavägen 23, Solna, Stockholm 171 65, Sweden., Byström S; Science for Life Laboratory, Department of Protein Science School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Tomtebodavägen 23, Solna, Stockholm 171 65, Sweden., Chen Y; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet Nobels väg 12A, Stockholm SE-171 77, Sweden; Department of Medicine, Karolinska Institutet, Stockholm, Sweden., Uhlén M; Science for Life Laboratory, Department of Protein Science School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Tomtebodavägen 23, Solna, Stockholm 171 65, Sweden., Mälarstig A; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet Nobels väg 12A, Stockholm SE-171 77, Sweden; Department of Medicine, Karolinska Institutet, Stockholm, Sweden., Czene K; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet Nobels väg 12A, Stockholm SE-171 77, Sweden., Hall P; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet Nobels väg 12A, Stockholm SE-171 77, Sweden; Department of Oncology, Södersjukhuset, Stockholm, Sweden., Schwenk JM; Science for Life Laboratory, Department of Protein Science School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Tomtebodavägen 23, Solna, Stockholm 171 65, Sweden. Electronic address: jochen.schwenk@scilifelab.se., Gabrielson M; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet Nobels väg 12A, Stockholm SE-171 77, Sweden. Electronic address: marike.gabrielson@ki.se.

Publikováno v: Translational oncology [Transl Oncol] 2022 Mar; Vol. 17, pp. 101339. Date of Electronic Publication: 2022 Jan 13.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Systematic Development of Sandwich Immunoassays for the Plasma Secretome.

Autor: Häussler RS; Division of Affinity Proteomics, Science for Life Laboratory, KTH - Royal Institute of Technology, Box 1031, 171 21, Solna, Sweden., Bendes A; Division of Affinity Proteomics, Science for Life Laboratory, KTH - Royal Institute of Technology, Box 1031, 171 21, Solna, Sweden., Iglesias M; Division of Cellular and Clinical Proteomics, Science for Life Laboratory, KTH - Royal Institute of Technology, Box 1031, 171 21, Solna, Sweden.; K.G. Jebsen - Thrombosis Research and Expertise Center (TREC), Department of Clinical Medicine, UiT - The Arctic University of Norway, 9010, Tromsø, Norway.; Division of Internal Medicine, University Hospital of North Norway, 9010, Tromsø, Norway., Sanchez-Rivera L; Division of Cellular and Clinical Proteomics, Science for Life Laboratory, KTH - Royal Institute of Technology, Box 1031, 171 21, Solna, Sweden., Dodig-Crnković T; Division of Affinity Proteomics, Science for Life Laboratory, KTH - Royal Institute of Technology, Box 1031, 171 21, Solna, Sweden., Byström S; Division of Affinity Proteomics, Science for Life Laboratory, KTH - Royal Institute of Technology, Box 1031, 171 21, Solna, Sweden., Fredolini C; Division of Affinity Proteomics, Science for Life Laboratory, KTH - Royal Institute of Technology, Box 1031, 171 21, Solna, Sweden., Birgersson E; Division of Affinity Proteomics, Science for Life Laboratory, KTH - Royal Institute of Technology, Box 1031, 171 21, Solna, Sweden., Dale M; Division of Affinity Proteomics, Science for Life Laboratory, KTH - Royal Institute of Technology, Box 1031, 171 21, Solna, Sweden., Edfors F; Division of Systems Biology, Science for Life Laboratory, KTH - Royal Institute of Technology, Box 1031, 171 21, Solna, Sweden., Fagerberg L; Division of Systems Biology, Science for Life Laboratory, KTH - Royal Institute of Technology, Box 1031, 171 21, Solna, Sweden., Rockberg J; Division of Protein Technology, Department of Protein Science, KTH - Royal Institute of Technology, 106 91, Stockholm, Sweden., Tegel H; Division of Protein Technology, Department of Protein Science, KTH - Royal Institute of Technology, 106 91, Stockholm, Sweden., Uhlén M; Division of Systems Biology, Science for Life Laboratory, KTH - Royal Institute of Technology, Box 1031, 171 21, Solna, Sweden.; Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, 2970, Hørsholm, Denmark., Qundos U; Atlas Antibodies AB, 168 69, Bromma, Sweden., Schwenk JM; Division of Affinity Proteomics, Science for Life Laboratory, KTH - Royal Institute of Technology, Box 1031, 171 21, Solna, Sweden.

Publikováno v: Proteomics [Proteomics] 2019 Aug; Vol. 19 (15), pp. e1900008. Date of Electronic Publication: 2019 Jul 22.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib.

Autor: Daneshmanesh AH; Department of Oncology-Pathology, Immune and Gene therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna, Stockholm, Sweden.; Karolinska Institutet, Stockholm, Sweden., Hojjat-Farsangi M; Department of Oncology-Pathology, Immune and Gene therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna, Stockholm, Sweden.; Karolinska Institutet, Stockholm, Sweden., Ghaderi A; Department of Oncology-Pathology, Immune and Gene therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna, Stockholm, Sweden.; Karolinska Institutet, Stockholm, Sweden., Moshfegh A; Department of Oncology-Pathology, Immune and Gene therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna, Stockholm, Sweden.; Karolinska Institutet, Stockholm, Sweden., Hansson L; Department of Oncology-Pathology, Immune and Gene therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna, Stockholm, Sweden.; Karolinska Institutet, Stockholm, Sweden.; Department of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden., Schultz J; Kancera AB, Karolinska Institutet Science Park, Stockholm, Sweden., Vågberg J; Kancera AB, Karolinska Institutet Science Park, Stockholm, Sweden., Byström S; Kancera AB, Karolinska Institutet Science Park, Stockholm, Sweden., Olsson E; Kancera AB, Karolinska Institutet Science Park, Stockholm, Sweden., Olin T; Kancera AB, Karolinska Institutet Science Park, Stockholm, Sweden., Österborg A; Department of Oncology-Pathology, Immune and Gene therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna, Stockholm, Sweden.; Karolinska Institutet, Stockholm, Sweden.; Department of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden., Mellstedt H; Department of Oncology-Pathology, Immune and Gene therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna, Stockholm, Sweden.; Karolinska Institutet, Stockholm, Sweden.; Department of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden.

Publikováno v: PloS one [PLoS One] 2018 Jun 01; Vol. 13 (6), pp. e0198038. Date of Electronic Publication: 2018 Jun 01 (Print Publication: 2018).